key: cord-0927481-l3zgtc1h authors: Mehta, A.; Vasudevan, S.; Parkash, A.; Sharma, A.; Vashist, T.; Krishna, V. title: COVID-19 Mortality in Cancer Patients: A Report from a Tertiary Cancer Centre in India date: 2020-09-15 journal: nan DOI: 10.1101/2020.09.14.20194092 sha: 38673dacb663b9502f6b5a58ed3fe95cf79298ce doc_id: 927481 cord_uid: l3zgtc1h Background: Cancer patients, especially those receiving cytotoxic therapy are assumed to have a higher probability of death from COVID-19. We have conducted this study to identify the Case Fatality Rate (CFR) in cancer patients with COVID-19 and have explored the relationship of various clinical factors to mortality in our patient cohort. Methods: All active cancer cases presented to the hospital from 8th June to 24 August 2020, and developed symptoms/ radiological features suspicious of COVID-19 were tested by Real-time polymerase chain reaction assay and/or cartridge-based nucleic acid amplification test from a combination of naso-oropharyngeal swab for SARS-CoV-2. Clinical data, treatment details, and outcomes were assessed from the medical records. Results: Of the total 3101 cancer patients admitted to the hospital, 1088 patients were tested and 186 patients were positive for SARS-CoV-2. The CFR in the cohort was 27/186 (14.5%). Univariate analysis showed that the risk of death was significantly associated with the presence of comorbidities [OR: 2.68; (95%CI: 1.13-6.32); P=0.02], multiple comorbidities [OR: 3.01; (95%CI: 1.02-9.07); P=0.046 for multiple vs. single], and the severity of COVID-19 presentation [OR: 27.48; (95%CI: 5.34-141.49); P=0.0001 for severe vs. not severe]. Among all comorbidities, diabetes [OR: 3.3; (95%CI: 1.35-8.09); P=0.008] and cardiovascular diseases [OR: 3.77; (95%CI: 1.02-13.91); P=0.045] were significant risk factors for death. The receipt of anticancer treatments including chemotherapy, surgery, radiotherapy, targeted therapy, and immunotherapy within a month before the onset of COVID-19 symptoms had no significant effect on the mortality of cancer patients. Conclusion: To the best of our knowledge, this is the first study from India reporting the CFR, clinical associations, and risk factors for mortality in SARS-CoV-2 infected cancer patients. Our study shows that the frequency of COVID-19 in cancer patients is high, and the CFR is 7.6 times more than the national average. Anticancer therapies did not increase the risk of death. Pre-existing comorbidities specially diabetes, multiple comorbidities, and severity of COVID-19 presenting symptoms are significantly linked with COVID-19 related death in the cohort. The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused unprecedented health and societal crises across the globe. This catastrophe however has victimized the cancer patients the most, adversely impacting diagnosis and treatment in about 55% of cases worldwide 1 . It is generally assumed that patients with cancer are at a higher risk of contracting COVID-19. Additionally, it is also postulated that the severity and resulting mortality is amplified in cancer patients with COVID-19 due to their elderly and the immunocompromised state further worsened by cancer treatment. Multiple studies from different geographical locations show that the case fatality rate (CFR) of the SARS-CoV-2 infected cancer patients varies from 3.7% to 61.5% (2) (3) (4) . Despite recent efforts, no clear consensus has been reached for the relation of mortality to demographics, cancer type, stage, and underlying comorbidities; and it may depend on the epidemiology and prevalent oncology practices (5, 6) . Various studies regarding the risk of treating cancer patients during the pandemic have shown contradictory results (7) (8) (9) (10) . Larger datasets acquired globally from different sources and geographic locations and rationally analyzed has the best potential to provide an effective risk-benefit calculus to assist oncologists to optimize the management and use anticancer treatments to restore outcomes to the pre-COVID 19 eras. We aim to describe the clinical and demographic characteristics and COVID-19 outcomes in a cohort of patients with cancer and symptomatic COVID-19. An attempt has also been made to assess the adverse effect of cytotoxic and other novel therapies on mortality in cancer patients with COVID-19, if any. The study is single-center, retrospective, conducted at a tertiary cancer care hospital. Patients with active cancer presented to the hospital between 8 th June to 20 th August 2020, and with confirmed COVID-19 infection were included. Clinical data, anticancer treatment details (performed within a month of COVID-19 diagnosis), clinical course, and outcome were retrieved from the hospital electronic medical records. The COVID-19 infection severity of patients was scored at the time of presentation by the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . treating physician according to the Ministry of Health and Family Welfare (Government of India) guidelines (11, 12) . The study has been approved by our Institutional Review Board (RGCIRC/IRB-BHR/61/2020) and was conducted according to the Declaration of Helsinki. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint software or MedCalc Statistical Software version 19.4.0. The reported P values are twosided and a P value<0.05 was considered statistically significant. A total of 3101 cancer patients were treated at the indoor facility of the center. One thousand and eighty-eight patients developed signs, symptoms, and/ or radiological features suspicious of COVID-19. Of these 186 tested positive for COVID-19 and formed the study cohort. The infection rate of COVID-19 among all cancer patients treated at the center was ~6% (186/3101) and 17.1% (186/1088) of the symptomatic and tested cancer patients. The clinical features are shown in Table 1 . Most patients had solid malignancies (82.3%); gastrointestinal cancer (21.5%) was the commonest cancer type. About 17.7% of cases presented with hematological malignancies. More than a quarter of cases (26.9%) were metastatic. Eighty-six patients (46.2%) presented at least a single comorbidity; hypertension (24.2%) and diabetes (18.3%) were the commonest. About 60% of cases were on active cancer treatment and had received cancer-directed treatment within a month before the onset of COVID-19 symptoms. The majority of patients were on chemotherapy (37%). The chief presenting symptoms of SARS-CoV-2 infection were fever (123/186, 66.1%, fatigue (26/186, 14%) and respiratory distress (25/186, 13.4%). The disease was presented severe in 9/186 (~5%) cases. The COVID-19 associated fatality rate in the cohort was 14.5% (27/ 186) [median follow-up duration: 63 days]. The CFR for hematological malignancies tended to be higher than the CFR for solid malignancies (7/33, 21.2% vs. 20/153, 13.1%). Severe COVID-19 infected cancer cases were managed by treatments including corticosteroids, hydroxychloroquine, remdesivir, tocilizumab and convalescent plasma therapy. Assisted ventilation had to be given to 12 patients (6.4%), however, all of them eventually developed COVID-19 related complications like pneumonitis and associated respiratory failure, septic shock or sudden cardiac arrest and succumbed to the disease. Next, we explored the differences between the cancer patients who died and those who survived the SARS-CoV-2 infection (Table 1 ). There was no significant difference between the survivors and the non-survivors with respect to age, gender, type of malignancy, and All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . cancer spread. Also, no significant effect on mortality was noted for the patients who had received anticancer therapy within the past month. Deceased patients displayed significantly higher rates of comorbidity compared to the cancer patients who survived (66.7% vs. 42.8%, P=0.035); patients with greater than one comorbidity had significantly inferior outcome than those with single or no comorbidity (P=0.004). Importantly, patients with diabetes experienced significantly more deaths than patients without diabetes (P=0.01) (Table 1) . Further, we observed that cancer patients presented with moderate and severe COVID-19 symptoms had significantly higher mortality than those presented with mild symptoms (P<0.0001). The logistic regression analysis (univariate) for death has been shown in The COVID-19 pandemic has raised several fears. One among these has been the increased propensity of cancer patients to contract COVID-19. In the current study, we found the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint incidence of COVID-19 to be ~6.0% against the national incidence of 0.32% in the general population and 0.29% as per European Centre for Disease Prevention and Control (Figure 1a ), the incidence in cancer patients is (>)15 fold higher (13, 14) . This on one hand can be ascribed to patients' factors, visitations, and admission to a health care facility with a high risk of contracting infection; may also be partly because of low testing rates in India and poor access to health care facilities. However, even when compared to the reported incidence in other high COVID-19 incidence nations like Brazil and the USA, the incidence is still 3 times higher and several-fold more than middle and low incidence countries ( Figure 1b ). While the present study does not explore the reasons for this alarmingly high occurrence of COVID-19 in cancer patients, it does establish the higher incidence of COVID-19 in cancer patients. The CFR in the present study was observed to be 14.5 % against the national average of 1.9% in the general population (7.6 times higher) as per the national database (Arogyasetu Application), 1.84% by John Hopkin COVID-19 tracker, and 1.7% as per the European Centre for Disease Prevention and Control (Figure 1c ) (13) (14) (15) . Two recent studies from the European continent have shown a far greater CFR in cancer patients with COVID-19. In the UK Coronavirus Cancer Monitoring Project, a CFR of 30.6% was observed, where 319 of the 1044 cancer patients with COVID-19 died with 92.5% had their death attributed directly to COVID-19 (9) . In another observational study by Pinato et al. of 890 cancer patients diagnosed with SARS-CoV-2, mortality was found to be 33.6% (10) . Similarly, high rates were noticed in a New York Hospital System where a CFR of 28% was observed (16) . A large systematic review of 52 studies by a group led by Kamal S Saini involving more than 18,000 cases of cancer with COVID-19, the probability of death was 25·6% (95% CI 22·0% to 29·9%; I 2 =48·9%) (4) . Relatively, lower CFR in the present study when contextualized to CFR in the general population shows the similar proportion to those observed elsewhere. This study once again establishes the far higher CFR in cancer patients with COVID-19. Unlike the previous retrospective studies from China, we did not find any significant association between cancer treatment and mortality (7, 8) (9, 17) . The All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint recent multi-center study by Pinato et al. in the European cancer patients and the and Cancer Consortium (CCC19) database study also strengthens the notion that cancer treatment is not associated with mortality (10, 18) . Similar to these studies we found that it is the underlying comorbid conditions and COVID-19 disease severity that are associated with adverse outcomes. Consistent with the CCC19 study we observed a higher burden of preexisting comorbidities (>1) to be associated with increased mortality (18) . Cardiovascular diseases and diabetes posed a higher risk of death in our cohort. It should be noted that comorbid conditions like diabetes frequently co-occur with hypertension or coronary artery disease in cancer patients and can further weaken the immune response escalating the risk of death due to 20) . Our study highlights the incredibly high rates of COVID-19 in cancer patients. More distressingly the CFR is 7.6 times more than the national average CFR for COVID-19. Anticancer therapies did have a significant effect on mortality in the cohort. Pre-existing comorbidities specially diabetes and more than one comorbidity are significantly linked with COVID-19 related deaths in cancer patients. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint Figure 1(a) Cumulative COVID-19 incidence per million population (India) Source: European Centre for Disease Prevention and Control (Data as on September 6, 2020) (14) All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint Figure 1b : The incidence of COVID 19 in general population ranges from 1.9% in Brazil to 0.13% in Pakistan (Data as on September 6, 2020) Source: European Centre for Disease Prevention and Control (Data as on September 6, 2020) (14) All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint Figure 1c : The COVID-19 Case Fatality Rate in India is 1.7% Source: European Centre for Disease Prevention and Control (Data as on September 6, 2020) (14) Supplementary Table 1 . Multivariate logistic regression analysis and risk of death All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.14.20194092 doi: medRxiv preprint World Health Organisation. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: Results of a rapid assessment Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center COVID-19 in persons with haematological cancers Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies COVID-19 infection in cancer patients: early observations and unanswered questions Do patients with cancer have a poorer prognosis of COVID-19? An experience Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer discov Revised Guidelines on Clinical Management of COVID -19. Government of India Online Resource] 12. Clinical management protocol: COVID-19. Government of India. Ministry of Health and Family Welfare Directorate General of Health Services Coronavirus Pandemic (COVID-19). 2020. Published online at OurWorldInData.org Accessed on 6th Accessed on 6th Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Determinants of COVID-19 disease severity in patients with cancer Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study